Searchable abstracts of presentations at key conferences in oncology

oa0001p052 | (1) | PacRim7

Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro

Winter Jean M , Mustafa Ebtihal H , Wang Shudong , Selth Luke A , Hickey Theresa E , Tilley Wayne D

This study evaluates the efficacy of two newly developed selective CDK9 inhibitors (CDK9i) across a panel of TNBC cell lines. MDA-MB-453, MFM-223, MDA-MB-468 and MDA-MB-231 TNBC cells were treated with increasing concentrations of two novel and highly selective CDK9 inhibitors and the effect on proliferation, apoptosis and expression of CDK9 targets determined. MDA-MB-453 and -468 cells showed significant growth inhibition with as little as 150 nM of CDK9i, evident 3 days afte...

oa0001p050 | (1) | PacRim7

Preclinical development of CDDD3-14, a potent and selective inhibitor of CDK4/6 for the treatment of breast cancer

Bantie Laychiluh , Tadesse Solomon , Likisa Jimma , Yu Mingfeng , Noll Benjamin , Heinemann Gary , Milne Robert , Albrecht Hugo , Wang Shudong

Deregulation of the CDK4/6-cyclin D-Rb-E2F pathway is common in subtypes (e.g. ER+/HER2−) of breast cancer, and activation/amplification of cyclin D1 (CCND1) and CDK4/6, or deletion/mutation of CDKN2A gene that encodes p16INK4a are the major mechanisms. Aberration in the upstream pathways such as PI3K/Akt/mTOR can also lead to the deregulation of the CDK4/6 axis, which drives carcinogenesis and development of resistance to therapies. Therefore, inhibition of CDK4/6 is a ...